MilliporeSigma Collaborates with Angiex to Speed Clinical Readiness of New Cancer Therapy


MilliporeSigma is supporting Angiex's ability to speed its lead oncology antibody drug candidate to clinical use.

MilliporeSigma announced a new collaboration with Angiex to support the biotechnology start-up's ability to speed its lead oncology antibody drug candidate to clinical use. Angiex is developing an antibody-drug conjugate (ADC) therapy for cancer against a vascular target, TM4SF1.

The collaboration with Angiex is the first project to be undertaken at MilliporeSigma's new biodevelopment center in Massachusetts. MilliporeSigma will give Angiex access to end-to-end process development tools, education programs and training to support its success.

"Companies benefit from our expertise and experience in developing GMP manufacturing processes for early clinical development programs," said Udit Batra, CEO, MilliporeSigma. "With an end-to-end approach, MilliporeSigma can facilitate and accelerate scaling and technical transfer for companies like Angiex."

MilliporeSigma's BioReliance End-to-End Solutions delivers products and services allowing biopharmaceutical companies to accelerate the progression of potential new therapies from the laboratory into clinical trial and on toward commercialization. The turnkey package includes process development, cGMP manufacturing, facility design, equipment for pilot-plant production, process and equipment training, technology transfer, equipment qualification and set-up for commercialization. To further support its global BioReliance End-to-End Solutions, MilliporeSigma will inaugurate its new biodevelopment center in Burlington, Massachusetts, in October 2017.

  • <<
  • >>